Michael A. Postow, MD

Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses nurses’ roles in treating patients receiving immunotherapy, especially combination checkpoint blockades, which are typically associated with higher risks of adverse events.